Management of primary and secondary non-responders to B cell depletion therapy in systemic lupus erythematosus: Results from the first 100 patients at a single centre

被引：0
|
作者：
Yusof, M. Y. Md [1 ,2 ]
Shaw, D. [1 ]
El-Sherbiny, Y. [1 ,2 ]
Dass, S. [1 ,2 ]
Savic, S. [1 ,2 ]
Rawstron, A. C. [1 ,3 ]
Vital, E. M. [1 ,2 ]
Emery, P. [1 ,2 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Unit, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4.05
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 39 条
  • [31] Itolizumab, a Novel Anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-Escalation Study
    Putterman, Chaim
    Furie, Richard
    Radhakrishnan, Jai
    Mathur, Vandana S.
    Polu, Krishna R.
    Connelly, Stephen
    Rothman, Joel M.
    Ng, Cherie T.
    Chinn, Leslie
    Fung, Maple M.
    Thomas, Dolca
    Kalunian, Kenneth
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 506 - 506
  • [32] TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
    Furie, Richard
    Bomba, Darrin
    Dall'era, Maria
    Prieto, Massiel
    Anderl, Janet
    Wang, Jinhai
    Kirk, Christopher
    Goel, Niti
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 776 - 777
  • [33] Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico
    Serrano-Arroyo, Lilliana
    Rios-Rivera, Rafael
    Gonzalez-Melendez, Ariana
    Vila, Luis M.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2860 - 2862
  • [34] De-escalation of radiation therapy after primary systemic therapy in non-metastatic breast cancer: patterns of recurrence from a real-world single-centre cohort of patients
    Banini, M.
    Valzano, M.
    Becherini, C.
    Visani, L.
    Scoccimarro, E.
    Salvestrini, V.
    Lorenzetti, V.
    Frosini, G.
    Peruzzi, A.
    Orzalesi, L.
    Nori, J.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    BREAST, 2023, 68 : S55 - S55
  • [35] First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients
    T. Brezina
    H. von Dewitz
    T. Schroeder
    S. Ullrich
    K. Nachtkamp
    G. Reifenberger
    B. Malzkorn
    M. Sabel
    R. Haas
    G. Kobbe
    Annals of Hematology, 2022, 101 : 607 - 616
  • [36] CC-220 Decreases B-Cell Subsets and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus (SLE) Patients and Is Associated with Skin Improvement: Pharmacodynamic Results from a Phase IIa Proof of Concept Study
    Werth, Victoria P.
    Furie, Richard
    Gaudy, Allison
    Ye, Ying
    Korish, Shimon
    Delev, Nikolay
    Hough, Douglas
    Weiswasser, Michael
    Choi, Suktae
    Schafer, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients
    Brezina, T.
    von Dewitz, H.
    Schroeder, T.
    Ullrich, S.
    Nachtkamp, K.
    Reifenberger, G.
    Malzkorn, B.
    Sabel, M.
    Haas, R.
    Kobbe, G.
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 607 - 616
  • [38] Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
    Merrill, J. T.
    van Vollenhoven, R. F.
    Buyon, J. P.
    Furie, R. A.
    Stohl, W.
    Morgan-Cox, M.
    Dickson, C.
    Anderson, P. W.
    Lee, C.
    Berclaz, P-Y
    Doerner, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) : 332 - 340
  • [39] Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as secondline therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.
    Yan, Zixun
    Hu, Yongxian
    Sheng, Lingshuang
    Wang, Li
    Cheng, Shu
    Wu, Wen
    Xu, Pengpeng
    Zhang, Muchen
    Wang, Chris
    Zhou, Zisong
    Yang, Su
    Qin, Yun
    Huang, He
    Zhao, Weili
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1234